Active Biotech AB Interim report January - March 2016
(Thomson Reuters ONE) -
Laquinimod
· The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting
multiple sclerosis (RRMS), with the aim to obtain market approval in the US and
Europe, is proceeding according to plan. Study results are expected in the first
half of 2017
· The clinical Phase 2 study ARPEGGIO for the treatment of primary progressive
multiple sclerosis (PPMS) is proceeding according to plan
· The clinical Phase 2 study LEGATO-HD for the treatment of Huntington's disease
is proceeding according to plan
· Extension studies with 0.6 mg laquinimod in patients from the Phase 3 studies
ALLEGRO and BRAVO are proceeding according to plan
· As earlier communicated the highest dose groups in the clinical studies
CONCERTO, ARPEGGIO and LEGATO-HD have been discontinued due to cardiovascular
events
Tasquinimod
· In March 2016, it was announced that the company plans to develop tasquinimod
to treat multiple myeloma and intends to seek a collaboration partner for the
project
· An expanded analysis of the secondary endpoints in the 10TASQ10 study was
presented at the ASCO GU Symposium in January 2016. The results showed that
tasquinimod had positive effects on both radiographic and PSA-based endpoints.
However, as previously communicated, overall survival (OS) was not extended,
prompting the discontinuation of all further development within prostate cancer
ANYARA, Paquinimod (57-57) and SILC (ISI)
· Out-licensing activities are continuing
Financial summary
MSEK Jan. - Mar. Full Year
2016 2015 2015
-------------------------------------------------------------------------------
Net sales 3.9 2.9 16.3
Operating loss -16.1 -57.4 -177.9
Loss for the period -16.8 -58.0 -193.5
Loss per share, before and after dilution (SEK) -0.19 -0.64 -2.15
Cash and cash equivalents (at the end of the 76.5 270.5 103.6
period)
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim report January - March 2016:
http://hugin.info/1002/R/2007548/742184.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#2007548]
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2016 - 08:30 Uhr
Sprache: Deutsch
News-ID 467129
Anzahl Zeichen: 3531
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - March 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
